Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)

计划入组 30 人 · 首次发布于 2014 年 11 月 7 日

A Study of VRN101099 in Patients With HER2-Positive Solid Tumors

计划入组 72 人 · 首次发布于 2025 年 2 月 4 日

Study of MT-5111 in HER2-positive Solid Tumors

计划入组 50 人 · 首次发布于 2019 年 7 月 23 日

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

CLK2 inhibitor (oral, solid tumors), Biosplice Therapeutics

Solid Biosciences Inc.

United States

Yichang Humanwell Oral Solid Dosage Plant

China

Arvinas

United States

Callio Therapeutics Initiates First-in-Human Trial of Dual-Payload ADC CLIO-8221 for HER2-Positive Solid Tumors

JSKN003 Shows Promise in HER2-Positive Solid Tumors and Platinum-Resistant Ovarian Cancer

Phase Ia Study of Novel Anti-HER2 Antibody-Drug Conjugate GQ1001 Shows Promise in Treating HER2 Positive Advanced Solid Tumors